Screener
Viridian Therapeutics, Inc. VRDN Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $284K+279% | $141K+95.8% | $132K+83.3% | $70.57M+81,958% | $75K+4.2% | ||
| $71.58M-17.4% | $77.63M+1.0% | $89.21M+24.0% | $86.26M+24.7% | $86.63M+54.2% | ||
| $54.98M+172% | $38.68M+126% | —— | —— | $20.22M+32.4% | ||
| $126.55M+18.4% | $116.31M+23.8% | $122.88M+40.4% | $110.58M+32.3% | $106.84M+47.9% | ||
| -$126.27M-18.3% | -$116.17M-23.8% | -$122.75M-40.3% | -$40.01M+52.1% | -$106.77M-47.9% | ||
| -44,460.6%+97,895pp | -82,389.4%+47,980pp | -92,991.7%+28,497pp | -56.7%+97,013pp | -142,356%-42,096pp | ||
| $8.31M+1,516% | $3.46M+529% | $3.28M+535% | $560K+5.9% | $514K-13.9% | ||
| -$851K-114% | $11.27M+62.0% | $2.39M-69.1% | $5.41M-20.3% | $6.03M-16.2% | ||
| -$127.12M-26.2% | -$104.9M-20.7% | -$120.36M-51.0% | -$34.6M+54.9% | -$100.74M-55.0% | ||
| -44,760.2%+89,553pp | -74,397.9%+46,313pp | -91,178%+19,551pp | -49%+89,124pp | -134,313.3%-44,045pp | ||
| —— | —— | —— | —— | —— | ||
| -$126.15M-18.3% | -$116.05M-23.8% | -$122.63M-40.4% | -$39.9M+52.1% | -$106.65M-48.0% | ||
| -44,419.4%+97,786pp | -82,303.5%+47,903pp | -92,900.8%+28,417pp | -56.5%+96,862pp | -142,205.3%-42,143pp | ||
| -$126.27M-18.3% | -$116.17M-23.8% | -$122.75M-40.3% | -$40.01M+52.1% | -$106.77M-47.9% |
FAQ
- What is Viridian Therapeutics, Inc.'s revenue?
- Viridian Therapeutics, Inc. (VRDN) generated $71.1M in revenue over the trailing twelve months, up 23220.3% year over year.
- Is Viridian Therapeutics, Inc. profitable?
- Viridian Therapeutics, Inc. is not currently profitable: it reported a net loss of $387.0M over the trailing twelve months, a -544.1% net margin.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Gross margin is 36.3% and operating margin is -569.7%, with a -544.1% net margin.
- Where does Viridian Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
